Company’s Scientific Leadership Reflected in 20 Accepted Papers and Posters
SAN RAMON, CALIF., June 6, 2023—Demonstrating continued scientific leadership in the contact lens and eye health fields, CooperVision is presenting 20 research papers and posters at the 2023 British Contact Lens Association (BCLA) Clinical Conference, which opens later this week in Manchester, England. These include a range of studies that highlight greater opportunities for contact lens fitting with more patients, plus multiple advances in myopia control and management.
“CooperVision’s commitment to partnering with eye care professionals (ECPs) worldwide requires more than innovative products. We constantly discover new, evidence-based data and insights that move vision and ocular health forward. During the BCLA Conference, it’s a privilege to educate our peers on multiple scientific initiatives and findings that will benefit millions of patients,” said Francis Erard, Vice President of Research & Development for CooperVision.
Prescribing More Toric & Multifocal Contact Lenses
A pioneer in sophisticated toric and multifocal contact lens options, the company is emphasizing both topics in its scientific presentations.
Visual Performance of Soft Toric Contact Lenses Over a Range of Levels of Low to Moderate Astigmatism (Read M., et al.) evaluated visual acuity, lens preference, and subjective vision in participants wearing a soft toric contact lens, a soft spherical contact lens, and sphero-cylindrical spectacle correction. Outcomes confirmed the need to fully correct astigmatic refractive errors of 0.75DC or more in soft lens wearers to optimize their vision.
A separate paper focuses on encouraging greater contact lens prescribing for presbyopes. Ease of Fitting Multifocal Contact Lenses (Sulley A., et al.) retrospectively analyzed 210 participants across three prospective studies, examining how many lens pairs were needed to achieve desired outcomes. Looking across three multifocal contact lenses types (including MyDay® multifocal), investigators determined that following the manufacturer fitting guides led to more than 85% first fit success—an affirmation that category improvements have created an easy experience for ECPs that will help with chair time.
Advancing Myopia Control & Management
Widely acknowledged as global authorities in myopia control and management, CooperVision experts and its research partners are speaking about various elements of the disease and its treatment in Manchester.
Dual Focus Contact Lenses Deliver a Myopia Control Signal to the Retinas of Highly Myopic Eyes (Nguyen M., et al.) enrolled subjects with high myopia (-6.50D to -9.25D), who were fit into single vision or MiSight® 1 day lenses. Accurate accommodation in the test group enabled the dual focus optic to deliver significant and consistent amounts of myopic defocus over a wide range of viewing distances, illustrating the potential for MiSight® 1 day use with this patient population that has an exponentially greater risk for maculopathy and other adverse sequalae.
Case Series on Myopia Progression in Children Beyond a Period of No Treatment Following 3 or 6 Years of MiSight® 1 day Treatment (Logan N., Jones S.) examined young adults who had worn the groundbreaking dual focus contact lens as part of the six-year clinic trial, then transitioned to a single vision lens for the seventh year. A subset whose refraction did not stabilize in year seven then returned to MiSight® 1 day wear for year eight. Investigators found that reinitiating treatment, even in late teens, resulted in either slowed or stopped myopia progression and axial elongation, with no reported issues in re-adapting to the dual focus design. Children are now prescribed MiSight® 1 day for myopia control in more than 30 countries around the world.
Understanding MiSight® 1 day among older wearers is the subject of Young Adult Acceptance of Dual Focus Myopia Control Soft Contact Lenses (Jones D., et al.). The Quality of Vision (QoV) questionnaire was administered multiple times to habitual single vision contact lens wearers aged 17-25 after their transition to MiSight® 1 day. Researchers determined that full day wear was well tolerated in young myopic adults, with mild increases in a limited number of vision symptoms having no impact on wear time. In fact, 70% of participants noted they were likely to continue wear given the likely myopia control benefits.
Initial visit success also pertains to myopia management. Orthokeratology Fitting Success Using New Software (Luensmann D., et al.) employed CooperVision’s Visavy™ platform to provide recommended parameters for Paragon® CRT or Paragon® CRT Dual Axis lenses for 30 participants across three study sites, requiring only topography image and entries for subjective refraction and white-to-white corneal diameter. Just two eyes (<3%) needed a lens parameter change after the initial Visavy™ recommendation. This 97% first fit success rate makes clear the time-saving and patient experience benefits of this new decision support technology in ortho-k practices.
CooperVision research collaborators at the BCLA Conference include Aston University’s School of Optometry, the Centre for Ocular Research & Education (CORE), Eurolens Research, Indiana University, Ocular Technology Group – International (OTGi), and the University of New South Wales.
Additional CooperVision presented and sponsored papers and posters can be previewed on the BCLA website, mobile app, or in person. The company is also posting video interviews with several paper and poster authors on its LinkedIn page.
The BCLA Clinical Conference and Exhibition attracts more than 900 U.K. and international contact lens professionals at all stages of their career. It runs from June 9-11, 2023, at the Manchester Central Convention Complex.
# # #
CooperVision, a division of CooperCompanies (NYSE:COO), is one of the world’s leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.
CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of more than 15,000, with products sold in over 130 countries. For more information, please visit www.coopercos.com.
Mike McDougall, APR, Fellow PRSA, FAAO, McDougall Communications
firstname.lastname@example.org or +1-585-434-2150